Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib's safety profile through 288 weeks (up to September 1, 2016) with an integrated database [8 phase III/II/Ib trials, 1...
Saved in:
| Published in | Journal of rheumatology Vol. 46; no. 1; p. 7 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Canada
01.01.2019
|
| Subjects | |
| Online Access | Get more information |
Cover
Loading…
| Abstract | Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib's safety profile through 288 weeks (up to September 1, 2016) with an integrated database [8 phase III/II/Ib trials, 1 longterm extension (LTE)].
The "all-bari-RA" group included patients who received any baricitinib dose. Placebo comparison was based on the 6 studies with 4 mg and placebo up to Week 24 ("placebo-4 mg" dataset). Dose response assessment was based on 4 studies with 2 mg and 4 mg including LTE data ("2 mg-4 mg-extended"). The uncommon events description used the non-controlled all-bari-RA.
There were 3492 patients who received baricitinib for 6637 total patient-years (PY) of exposure (median 2.1 yrs, maximum 5.5 yrs). No differences in rates of death, adverse events leading to drug discontinuation, malignancies, major adverse cardiovascular event (MACE), or serious infections were seen for 4 mg versus placebo or for 4 mg versus 2 mg. Infections including herpes zoster were significantly more frequent for 4 mg versus placebo. Deep vein thrombosis/pulmonary embolism were reported with 4 mg but not placebo [all-bari-RA incidence rate (IR) 0.5/100 PY]; the IR did not differ between doses (0.5 vs 0.6/100 PY, 2 mg vs 4 mg, respectively) or compared to published RA rates. All-bari-RA had 6 cases of lymphoma (IR 0.09/100 PY), 3 gastrointestinal perforations (0.05/100 PY), 10 cases of tuberculosis (all in endemic areas; 0.15/100 PY), and 22 all-cause deaths (0.33/100 PY). IR for malignancies (0.8/100 PY) and MACE (0.5/100 PY) were low and did not increase with prolonged exposure.
In this integrated analysis of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy. Trial registration numbers: NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT01721044, NCT01721057, NCT01711359, and NCT01885078 at clinicaltrials.gov. |
|---|---|
| AbstractList | Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib's safety profile through 288 weeks (up to September 1, 2016) with an integrated database [8 phase III/II/Ib trials, 1 longterm extension (LTE)].
The "all-bari-RA" group included patients who received any baricitinib dose. Placebo comparison was based on the 6 studies with 4 mg and placebo up to Week 24 ("placebo-4 mg" dataset). Dose response assessment was based on 4 studies with 2 mg and 4 mg including LTE data ("2 mg-4 mg-extended"). The uncommon events description used the non-controlled all-bari-RA.
There were 3492 patients who received baricitinib for 6637 total patient-years (PY) of exposure (median 2.1 yrs, maximum 5.5 yrs). No differences in rates of death, adverse events leading to drug discontinuation, malignancies, major adverse cardiovascular event (MACE), or serious infections were seen for 4 mg versus placebo or for 4 mg versus 2 mg. Infections including herpes zoster were significantly more frequent for 4 mg versus placebo. Deep vein thrombosis/pulmonary embolism were reported with 4 mg but not placebo [all-bari-RA incidence rate (IR) 0.5/100 PY]; the IR did not differ between doses (0.5 vs 0.6/100 PY, 2 mg vs 4 mg, respectively) or compared to published RA rates. All-bari-RA had 6 cases of lymphoma (IR 0.09/100 PY), 3 gastrointestinal perforations (0.05/100 PY), 10 cases of tuberculosis (all in endemic areas; 0.15/100 PY), and 22 all-cause deaths (0.33/100 PY). IR for malignancies (0.8/100 PY) and MACE (0.5/100 PY) were low and did not increase with prolonged exposure.
In this integrated analysis of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy. Trial registration numbers: NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT01721044, NCT01721057, NCT01711359, and NCT01885078 at clinicaltrials.gov. |
| Author | Takeuchi, Tsutomu Macias, William L Rooney, Terence Cardillo, Tracy E Riddle Camp, Jennifer Chen, Lei Hyslop, David L Dickson, Christina L Winthrop, Kevin L Ishii, Taeko Genovese, Mark C Smolen, Josef S |
| Author_xml | – sequence: 1 givenname: Josef S surname: Smolen fullname: Smolen, Josef S email: josef.smolen@meduniwien.ac.at, josef.smolen@meduniwien.ac.at organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University. josef.smolen@meduniwien.ac.at – sequence: 2 givenname: Mark C orcidid: 0000-0001-5294-4503 surname: Genovese fullname: Genovese, Mark C organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University – sequence: 3 givenname: Tsutomu surname: Takeuchi fullname: Takeuchi, Tsutomu organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University – sequence: 4 givenname: David L surname: Hyslop fullname: Hyslop, David L organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University – sequence: 5 givenname: William L surname: Macias fullname: Macias, William L organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University – sequence: 6 givenname: Terence surname: Rooney fullname: Rooney, Terence organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University – sequence: 7 givenname: Lei surname: Chen fullname: Chen, Lei organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University – sequence: 8 givenname: Christina L surname: Dickson fullname: Dickson, Christina L organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University – sequence: 9 givenname: Jennifer surname: Riddle Camp fullname: Riddle Camp, Jennifer organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University – sequence: 10 givenname: Tracy E surname: Cardillo fullname: Cardillo, Tracy E organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University – sequence: 11 givenname: Taeko surname: Ishii fullname: Ishii, Taeko organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University – sequence: 12 givenname: Kevin L surname: Winthrop fullname: Winthrop, Kevin L organization: J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University Medical Center; T. Takeuchi, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Keio University; D.L. Hyslop, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; W. Macias, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Rooney, MD, Lilly Research Laboratories, Eli Lilly and Co., USA; L. Chen, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., USA; C.L. Dickson, BS Pharm, Lilly Research Laboratories, Eli Lilly and Co., USA; J. Riddle Camp, BA, Lilly Research Laboratories, Eli Lilly and Co., USA; T.E. Cardillo, MSN, Lilly Research Laboratories, Eli Lilly and Co., USA; T. Ishii, MD, PhD, Lilly Research Laboratories, Eli Lilly and Co., Japan; K.L. Winthrop, MD, MPH, Oregon Health Sciences University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30219772$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1j8lOwzAURb0oogMs2SL_QIqHxI6XpWKSiqggSLCqnPhZeVWTVI5b1L-nFWV1N0fn6I7JoO1aIOSGs6nMjblbhxp2zZRrLhUfkBGTPEu4El9DMu77NWNcpSq_JEPJBDdaixHZfVgP8UCXofO4Adp5em8DVhixxZJiS5c2IrSxpz8YazqrIu6Bvp9CNnbo6CzEOhzxM9DtIVBBv8GGnr6CQ9vSAhs4qYoANjZH2RW58HbTw_V5J-Tz8aGYPyeLt6eX-WyRVFKKmHjLuarKsvROGp9lwubacFNJ52QK2jCnmOepk8xmzudMW2aEdLnTzDtVajEht3_e7a5swK22ARsbDqv__-IX3SNezg |
| CitedBy_id | crossref_primary_10_1080_14740338_2020_1774550 crossref_primary_10_1080_14740338_2020_1799975 crossref_primary_10_1093_ecco_jcc_jjz206 crossref_primary_10_1007_s00393_020_00768_5 crossref_primary_10_3390_molecules25071600 crossref_primary_10_1136_rmdopen_2020_001374 crossref_primary_10_1136_rmdopen_2021_001892 crossref_primary_10_1136_rmdopen_2023_004007 crossref_primary_10_1007_s40266_021_00856_4 crossref_primary_10_2222_jsv_71_45 crossref_primary_10_1093_rap_rkac032 crossref_primary_10_1186_s13075_024_03358_x crossref_primary_10_1136_rmdopen_2020_001370 crossref_primary_10_1007_s12688_019_0266_7 crossref_primary_10_1055_a_1294_1580 crossref_primary_10_1093_rheumatology_keaa895 crossref_primary_10_1016_j_gastre_2021_01_003 crossref_primary_10_1002_acr_24007 crossref_primary_10_1097_RHU_0000000000002136 crossref_primary_10_1016_j_jfma_2021_03_014 crossref_primary_10_1093_ibd_izae100 crossref_primary_10_3390_jcm8070938 crossref_primary_10_3238_arztebl_m2022_0064 crossref_primary_10_1080_14740338_2020_1743263 crossref_primary_10_1016_j_reumae_2020_04_008 crossref_primary_10_1080_1744666X_2022_2072298 crossref_primary_10_1136_rmdopen_2019_000942 crossref_primary_10_14412_1996_7012_2019_3_102_108 crossref_primary_10_3390_medicina61010054 crossref_primary_10_1186_s13063_022_06356_z crossref_primary_10_3389_fmed_2020_607725 crossref_primary_10_1038_s41598_020_78925_8 crossref_primary_10_1016_j_jaci_2021_08_010 crossref_primary_10_3390_jcm13103000 crossref_primary_10_1080_17512433_2020_1702878 crossref_primary_10_1016_j_rgmxen_2021_08_009 crossref_primary_10_1021_acs_jmedchem_0c01467 crossref_primary_10_1177_12034754221141680 crossref_primary_10_1007_s40265_020_01349_1 crossref_primary_10_1136_annrheumdis_2021_221051 crossref_primary_10_1007_s00108_019_00669_z crossref_primary_10_1177_17562848211054710 crossref_primary_10_1016_j_rcreu_2020_05_007 crossref_primary_10_1016_j_intimp_2020_106749 crossref_primary_10_1111_bph_15204 crossref_primary_10_2174_2210303113666221103104829 crossref_primary_10_1016_j_jaad_2021_02_028 crossref_primary_10_1002_cpdd_843 crossref_primary_10_1136_annrheumdis_2020_218398 crossref_primary_10_1016_S2665_9913_20_30032_1 crossref_primary_10_3389_fcell_2023_1205590 crossref_primary_10_1097_CM9_0000000000000711 crossref_primary_10_1136_rmdopen_2022_002236 crossref_primary_10_1080_14656566_2022_2076594 crossref_primary_10_1007_s40265_020_01293_0 crossref_primary_10_3238_PersDerma_2021_06_18_04 crossref_primary_10_1002_der2_65 crossref_primary_10_3390_ph15010048 crossref_primary_10_1080_14728214_2024_2445508 crossref_primary_10_1007_s12688_020_00364_0 crossref_primary_10_1136_rmdopen_2023_003918 crossref_primary_10_1136_annrheumdis_2018_214846 crossref_primary_10_1007_s40744_021_00317_9 crossref_primary_10_1021_acs_jmedchem_1c00963 crossref_primary_10_1016_j_jdcr_2019_07_005 crossref_primary_10_1007_s00393_022_01237_x crossref_primary_10_3390_cancers13112611 crossref_primary_10_1007_s40744_023_00624_3 crossref_primary_10_2147_DDDT_S475005 crossref_primary_10_5114_reum_2020_102006 crossref_primary_10_3390_ph12010037 crossref_primary_10_4103_ijt_ijt_28_21 crossref_primary_10_22159_ijpps_2022v14i11_46171 crossref_primary_10_1038_s41375_020_01087_z crossref_primary_10_1002_prp2_537 crossref_primary_10_1177_1759720X211047662 crossref_primary_10_1038_s41584_023_01062_9 crossref_primary_10_3390_biom10071002 crossref_primary_10_1016_j_msard_2021_103057 crossref_primary_10_2147_DHPS_S272411 crossref_primary_10_1007_s12026_021_09173_9 crossref_primary_10_1016_j_bsheal_2021_06_001 crossref_primary_10_1097_BOR_0000000000000810 crossref_primary_10_1093_ecco_jcc_jjaa233 crossref_primary_10_1007_s00296_020_04612_6 crossref_primary_10_2217_imt_2022_0109 crossref_primary_10_3390_jcm12082893 crossref_primary_10_1177_1759720X20930116 crossref_primary_10_1007_s40264_021_01082_y crossref_primary_10_1016_j_clinthera_2021_06_008 crossref_primary_10_1111_jdv_16948 crossref_primary_10_21518_2079_701X_2021_2_76_84 crossref_primary_10_1080_1744666X_2022_2039630 crossref_primary_10_1038_s41584_021_00593_3 crossref_primary_10_1016_j_crphar_2024_100178 crossref_primary_10_1021_acscatal_0c03622 crossref_primary_10_1080_14740338_2022_2020247 crossref_primary_10_3390_jcm9103319 crossref_primary_10_1371_journal_pone_0288757 crossref_primary_10_1080_1744666X_2022_2047022 crossref_primary_10_3389_fmed_2021_737079 crossref_primary_10_1002_advs_202412010 crossref_primary_10_1080_14397595_2020_1782049 crossref_primary_10_3390_biomed3020021 crossref_primary_10_1016_j_ccm_2019_07_003 crossref_primary_10_1002_art_42862 crossref_primary_10_1007_s40744_021_00305_z crossref_primary_10_1016_j_rgmx_2021_03_002 crossref_primary_10_3389_fmed_2019_00045 crossref_primary_10_3390_biomedicines10092324 crossref_primary_10_1016_j_gastrohep_2021_01_007 crossref_primary_10_1016_j_medcli_2021_05_011 crossref_primary_10_1055_a_2246_6536 crossref_primary_10_1136_rmdopen_2021_002012 crossref_primary_10_1136_ard_2023_223916 crossref_primary_10_1080_14712598_2020_1817372 crossref_primary_10_1007_s40266_020_00775_w crossref_primary_10_1007_s00393_019_00705_1 crossref_primary_10_1136_annrheumdis_2021_220822 crossref_primary_10_1016_S2665_9913_20_30059_X crossref_primary_10_1007_s10787_020_00757_9 crossref_primary_10_1111_1756_185X_13748 crossref_primary_10_1002_acr2_11479 crossref_primary_10_3389_fimmu_2024_1437512 crossref_primary_10_1016_j_medcle_2021_05_012 crossref_primary_10_1007_s40744_021_00410_z crossref_primary_10_1016_j_jaad_2020_06_051 crossref_primary_10_1007_s40272_023_00594_7 crossref_primary_10_2147_CCID_S376096 crossref_primary_10_1136_rmdopen_2022_002614 crossref_primary_10_1136_rmdopen_2022_002735 crossref_primary_10_1126_scitranslmed_aav7561 crossref_primary_10_1016_j_idc_2020_02_006 crossref_primary_10_1016_j_reuma_2020_04_011 crossref_primary_10_1007_s10067_021_05911_4 crossref_primary_10_1016_j_reumae_2020_06_006 crossref_primary_10_1080_13543784_2019_1692812 crossref_primary_10_1016_j_autrev_2020_102523 crossref_primary_10_1093_rheumatology_kead198 crossref_primary_10_3390_ph14070664 crossref_primary_10_1007_s10067_023_06513_y crossref_primary_10_1007_s12016_020_08786_6 crossref_primary_10_1136_rmdopen_2021_001595 crossref_primary_10_1136_annrheumdis_2019_216852 crossref_primary_10_1016_j_ejim_2019_05_022 crossref_primary_10_1093_mr_roac089 crossref_primary_10_1136_annrheumdis_2020_218690 crossref_primary_10_1016_S2213_2600_21_00358_1 crossref_primary_10_1007_s11926_020_00931_6 crossref_primary_10_1016_j_autrev_2018_12_009 crossref_primary_10_1093_mrcr_rxac098 crossref_primary_10_1002_art_41697 crossref_primary_10_1007_s40264_023_01333_0 crossref_primary_10_1080_1744666X_2019_1608821 crossref_primary_10_1016_j_rcreue_2020_10_001 crossref_primary_10_1080_14397595_2019_1583711 crossref_primary_10_1080_14787210_2021_1864327 crossref_primary_10_1038_s41584_024_01169_7 crossref_primary_10_1016_j_autrev_2019_102421 crossref_primary_10_1097_BOR_0000000000000796 crossref_primary_10_1016_j_rhum_2020_10_187 crossref_primary_10_1002_jmv_29100 crossref_primary_10_1136_ard_2024_225759 crossref_primary_10_2147_JIR_S219586 crossref_primary_10_1055_a_1247_4252 crossref_primary_10_7759_cureus_20024 crossref_primary_10_3899_jrheum_2023_1062 crossref_primary_10_2217_imt_2018_0178 crossref_primary_10_1093_rheumatology_keaa576 crossref_primary_10_1093_rheumatology_keae012 crossref_primary_10_1016_j_phrs_2022_106359 crossref_primary_10_1016_j_ejphar_2020_173505 crossref_primary_10_1136_ard_2023_225473 crossref_primary_10_3390_cells12141905 crossref_primary_10_1186_s13075_020_2125_2 crossref_primary_10_1136_ard_2023_223850 crossref_primary_10_1155_2022_6852189 crossref_primary_10_3390_nano11082005 crossref_primary_10_3390_medicina58020309 crossref_primary_10_1038_s41598_022_10777_w crossref_primary_10_3390_ijms21197390 crossref_primary_10_1016_j_lfs_2021_119655 crossref_primary_10_3390_cells9081876 crossref_primary_10_1159_000541488 crossref_primary_10_1177_1759720X20936059 crossref_primary_10_1016_S1473_3099_20_30262_0 crossref_primary_10_3390_jcm13237185 crossref_primary_10_1177_1060028019839650 crossref_primary_10_1002_cti2_1425 crossref_primary_10_1016_j_idc_2020_02_014 crossref_primary_10_1136_rmdopen_2020_001395 crossref_primary_10_4081_reumatismo_2024_1620 crossref_primary_10_1136_rmdopen_2019_000898 crossref_primary_10_1016_j_rhum_2021_10_174 crossref_primary_10_1145_3382769 crossref_primary_10_1136_rmdopen_2022_002280 crossref_primary_10_1007_s00296_022_05270_6 crossref_primary_10_1016_j_reuma_2020_06_011 crossref_primary_10_1136_bmjopen_2023_072300 crossref_primary_10_1097_FJC_0000000000001470 crossref_primary_10_1136_annrheumdis_2020_218510 crossref_primary_10_1016_j_jaci_2021_11_001 crossref_primary_10_1093_bjd_ljad229 crossref_primary_10_3389_fimmu_2025_1494283 crossref_primary_10_1021_acs_jmedchem_1c00335 crossref_primary_10_14412_1996_7012_2024_6_21_35 crossref_primary_10_14412_1995_4484_2020_304_316 crossref_primary_10_1093_mr_roae077 crossref_primary_10_1038_s41392_021_00791_1 crossref_primary_10_1016_j_semarthrit_2020_07_007 |
| ContentType | Journal Article |
| DBID | NPM |
| DOI | 10.3899/jrheum.171361 |
| DatabaseName | PubMed |
| DatabaseTitle | PubMed |
| DatabaseTitleList | PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 30219772 |
| Genre | Journal Article |
| GroupedDBID | --- .55 .GJ 0R~ 123 18M 1KJ 3O- 4.4 53G 5RE 6PF AAQQT AAWTL ABCQX ABJNI ACGFO ACGFS ADCBC AENEX AFFNX AI. ALMA_UNASSIGNED_HOLDINGS BR6 EBS EJD EMOBN F5P H13 HZ~ J5H L7B MJL NPM O9- P0W P2P RHI SJN TJE VH1 W2D X7M XBR XDU XOL YCJ YQJ ZGI ZXE ZXP |
| ID | FETCH-LOGICAL-c332t-fa116cbbbfd39f552a87919c3dd34e790d60f14d30a5df807a0923d8d70fd6b72 |
| ISSN | 0315-162X |
| IngestDate | Thu Jan 02 22:59:46 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | RHEUMATOID ARTHRITIS BARICITINIB CLINICAL TRIALS SAFETY JANUS KINASE INHIBITOR |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c332t-fa116cbbbfd39f552a87919c3dd34e790d60f14d30a5df807a0923d8d70fd6b72 |
| ORCID | 0000-0001-5294-4503 |
| OpenAccessLink | https://www.jrheum.org/content/jrheum/46/1/7.full.pdf |
| PMID | 30219772 |
| ParticipantIDs | pubmed_primary_30219772 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-01-00 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-00 |
| PublicationDecade | 2010 |
| PublicationPlace | Canada |
| PublicationPlace_xml | – name: Canada |
| PublicationTitle | Journal of rheumatology |
| PublicationTitleAlternate | J Rheumatol |
| PublicationYear | 2019 |
| References | 31787595 - J Rheumatol. 2019 Dec;46(12):1648-1649 |
| References_xml | – reference: 31787595 - J Rheumatol. 2019 Dec;46(12):1648-1649 |
| SSID | ssj0016468 |
| Score | 2.6267827 |
| Snippet | Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We... |
| SourceID | pubmed |
| SourceType | Index Database |
| StartPage | 7 |
| Title | Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30219772 |
| Volume | 46 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBabFkIuJX2naYMOvS1O_ZLkPaalTQiklGYD6SlIlkRMuvaStQ_tT-mv7Ywke52Q0MdFGMvItuaT-DTSN0PI24JZyQpTwkCSPMq54pFkJo84kPGUWQskHQXOJ5_50Vl-fM7OJ5Nfo1NLXav2y5936kr-x6pwD-yKKtl_sOzQKNyAa7AvlGBhKP_KxqfSGifxc3m3kfe9h6VvWbVVXSn0ZHzxUVODhO3AzW3Tr5emA57aVBpd85cuqpF_AI9zTtPpN0D_ym3hwOBHjQg2Ne9PpN9DZ69Dq2Mv_ekCd_37jQa7drMemhre5XM6olpo7audyyuD-VkcjlZd2yy6AXk_Vt-b5XAQP-glgscCRVKDxyIotRIWJdylUR9m4eCIHKPNT6nirokeowLiRO_-bT-BlbYP6T4y-nLhrJ4BiQGOm_659lbc7b5qg2xAiSlV0Q8U9qd47kSWw5_46K34Ve9ufNMW2ezbubVucfxlvk0eBUvRA4-ix2Ri6idk8yQcrXhKOg8mGsBEG0tHYKJVTXswUcQK9WCiazDRAUz-AQQTTakDE_VgoggmbGoA0zNy9unj_MNRFHJyRGWWpW1kZZLwUilldTazjKWyELNkVmZaZ7kRs1jz2Ca5zmLJtC1iIWNYQuhCi9hqrkT6nDyom9q8JDTNFNDvkmuZm1ybpCigW4EfWyEE58LukBe-wy6WPvDKRd-Vr-6t2SVba8S9Jg8tjHTzBmhjq_acBX8Du_RvlQ |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+Profile+of+Baricitinib+in+Patients+with+Active+Rheumatoid+Arthritis+with+over+2+Years+Median+Time+in+Treatment&rft.jtitle=Journal+of+rheumatology&rft.au=Smolen%2C+Josef+S&rft.au=Genovese%2C+Mark+C&rft.au=Takeuchi%2C+Tsutomu&rft.au=Hyslop%2C+David+L&rft.date=2019-01-01&rft.issn=0315-162X&rft.volume=46&rft.issue=1&rft.spage=7&rft_id=info:doi/10.3899%2Fjrheum.171361&rft_id=info%3Apmid%2F30219772&rft_id=info%3Apmid%2F30219772&rft.externalDocID=30219772 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0315-162X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0315-162X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0315-162X&client=summon |